The synthesis of 6-phenyl-atevirdine (17), a lipophilic derivative of the potent HIV-1 reverse transcriptase inhibitor atevirdine (1), is described. The title compound was prepared from dithioacetale 2 via keteneaminal 4 and the nitropyridine derivative 10. Unexpectedly, no anti HIV activity was observed for the novel atevirdine derivative 17. The key intermediates 6, 8 and 10 could also be prepared
The compounds of formula (I) in which R1 is 1-4C-alkoxy, , A is 1-4C-alkylene, B represents 3H-imidazo (4,5b) pyridin-2-yl, 3H-imidazo (4,5-b) pyridin-2-yl substituted by R2 and/or R8, 9H-purin-8yl or 9H-purin-8-yl substituted by R4 and/or R5 are effective iNOS inhibitors.
The compounds of formula I
in which R1 is 1-4C-alkoxy, A is 1-4C-alkylene, B represents 3H-imidazo[4,5-b]pyridin-2-yl, 3H-imidazo[4,5-b]pyridin-2-yl substituted by R2 and/or R3, 9H-purin-8-yl or 9H-purin-8-yl substituted by R4 and/or R5, are effective iNOS inhibitors.
Compounds, pharmaceutical compositions, kits and methods are provided for use with glucokinase that comprise a compound selected from the group consisting of formula (I) wherein the variables are as defined herein.